Sirolimus

mTOR, mammalian target of rapamycin.

That's named after the drug that targets that receptor.

Rapamycin targets the immune system and in some sense mimics fasting.

Okay, this is broadly speaking.

Keep in mind that the studies showing extension of life in different species, including mice, show that being fairly dramatically sub-maintenance caloric extends lifespan, but you're also potentially sub-happiness when you're that sub-caloric.

Okay.

You might have seen it as Sirolimus.

And he prescribes it for longevity enhancing purposes.

Ah.

Before, but I remember when NMN, rapamycin, NAD, sublingual, uh, mix it in the yogurt, do all of this stuff.

I remember when that was, you know, gonna make us all live to 150, and w- what is the state of the world of longevity drug supplements now? What's happening with that-

Yeah, I just did-

... an episode with Peter Attia.

So here's the deal as I understand it.

Peter is pretty bullish on rapamycin.

Um, remember that mTOR, which is expressed at very high levels in essentially all cells of the brain and body during development, declines across the lifespan.

mTOR, mammalian target of rapamycin.

And so we talked about mTOR, this growth-promoting factor.

Rapamycin inhibits mTOR.

Again, if people remember, I said mTOR stands for mechanistic target of rapamycin.

They named mTOR after the drug.

So if you think about mTOR as a volume knob, nutrients are high, mTOR gets turned up, that promotes growth.

Nutrients are low, mTOR gets turned down, that promotes stress resistance and shuts down growth and reproduction.

Rapamycin is a drug that turns the volume down on mTOR.

And what we have observed is that in every animal where it's ever been tested in the lab, if you genetically turn down mTOR, so we can do gene therapies and things like that to turn down mTOR, or if you use the drug rapamycin, you cause the organisms to live longer and they seem to age more slowly.

And that's all about how do you increase that quality of life and extend lifespan.

You know, rapamycin trials, which I think are very, very early comparatively to stem cell therapy, which is pretty understood, as well as, um, Loyal, which is about to get approval.

Rapamycin is a very exciting frontier that we're watching come to fruition.

Um-

Yeah, I've heard about that one at conferences.

And we're able to, in conjunction with senolytic therapies, with therapies that support mitophagy and autophagy, actually regain the cellular function and get people working again.

And that could be rapamycin, that could be KPV or MSH, that could be fisetin and urolithin A and spermidine and all these really interesting things right now.

Rapamycin is such a whole nother interesting conversation.

I probably got more Rapamycin data than almost anyone I think at this point.

That'll have to be for a follow up.

So that's exciting.

We've spoken about this before, but I remember when NMN, rapamycin, NAD, sublingual, uh, mix it in the yogurt, do all of this stuff.

I remember when that was, you know, gonna make us all live to 150, and w- what is the state of the world of longevity drug supplements now? What's happening with that-

Yeah, I just-

... did an episode with Peter Attia.

So here's the deal as I understand it.

Peter is pretty bullish on rapamycin.

Um, remember that mTOR, which is expressed at very high levels in essentially all cells of the brain and body during development, declines across the lifespan.

mTOR, mammalian target of rapamycin.